Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (71-80 of 383) with videos related to

Pageof 39
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2002
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemiaYanming Zhang, Pamela Strissel, Reiner Strick, et al.
Blood|February 8, 2008
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyRichard A Larson, Brian J Druker, Francois Guilhot, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2021
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapyWilliam A Clarke, Etienne Chatelut, Alan K Fotoohi, et al.
Cancer|January 19, 2006
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology GroupWilliam R Friedenberg, Montserrat Rue, Emily A Blood, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2020
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell TransplantationAmy Y Wang, Justin Kline, Wendy Stock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BLewis R Silverman, David R McKenzie, Bercedis L Peterson, et al.
Blood Advances|September 7, 2021
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapyAnand Ashwin Patel, Alexandra E Rojek, Michael W Drazer, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
<i>In Vivo</i> Simvastatin and Brain Radiation in a Model of HER2 <sup>+</sup> Inflammatory Breast Cancer Brain MetastasisSwaminathan Kumar, Richard A Larson, Shane Stecklein, et al.
Future Oncology (London, England)|December 16, 2022
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trialJorge E Cortes, Andreas Hochhaus, Naoto Takahashi, et al.
British Journal of Haematology|June 16, 2017
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacyPierre Fenaux, Petra Muus, Hagop Kantarjian, et al.
Pageof 39

Showing results (71-80 of 383) with videos related to

Sort By:
Pageof 39
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2002
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemiaYanming Zhang, Pamela Strissel, Reiner Strick, et al.
Blood|February 8, 2008
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyRichard A Larson, Brian J Druker, Francois Guilhot, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2021
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapyWilliam A Clarke, Etienne Chatelut, Alan K Fotoohi, et al.
Cancer|January 19, 2006
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology GroupWilliam R Friedenberg, Montserrat Rue, Emily A Blood, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2020
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell TransplantationAmy Y Wang, Justin Kline, Wendy Stock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BLewis R Silverman, David R McKenzie, Bercedis L Peterson, et al.
Blood Advances|September 7, 2021
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapyAnand Ashwin Patel, Alexandra E Rojek, Michael W Drazer, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
<i>In Vivo</i> Simvastatin and Brain Radiation in a Model of HER2 <sup>+</sup> Inflammatory Breast Cancer Brain MetastasisSwaminathan Kumar, Richard A Larson, Shane Stecklein, et al.
Future Oncology (London, England)|December 16, 2022
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trialJorge E Cortes, Andreas Hochhaus, Naoto Takahashi, et al.
British Journal of Haematology|June 16, 2017
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacyPierre Fenaux, Petra Muus, Hagop Kantarjian, et al.
Pageof 39